Table 8.

Summary statistics for the owner efficacy scores from Day 1 to VF

Response	Visits	Robenacoxib (s.c. + oral)	Meloxicam s.c. + oral placebo	P value (Mann–Whitney test)	Quotient robenacoxib:meloxicam (RMANCOVA)		P value (RMANCOVA)	Transformation for RMANCOVA analysis
		Mean (SD)	Mean (SD)		Mean	95% CI		Exponential	P value for normality (Shapiro-Wilks test)
Level of activity	D1-VF	0.62 (0.53)	0.64 (0.61)	0.96	0.972	0.658–1.373	0.87	0 (log)	<0.0001
Behaviour	D1-VF	0.29 (0.38)	0.31 (0.34)	0.57	1.285	0.731–2.240	0.34	−1 (reciprocal)	<0.0001
Appetite	D1-VF	0.38 (0.48)	0.37 (0.49)	0.69	1.006	0.551–1.672	0.98	−1 (reciprocal)	<0.0001
Interaction	D1-VF	0.23 (0.34)	0.26 (0.33)	0.70	1.306	0.696–2.452	0.36	−1 (reciprocal)	<0.0001
Global owner score	D1-VF	1.52 (1.42)	1.58 (1.45)	0.87	1.050	0.719–1.482	0.78	0 (log)	<0.0001

CI: confidence interval; VF: final visit.

Values are mean (SD) for each group and quotient values with 95% CI for the ratio robenacoxib/meloxicam. All assessments made by the owners are secondary end points. Assessments were made daily from the day after surgery (Day 1) to VF.

Non-inferiority of robenacoxib versus meloxicam was concluded if the lower limit of the 95% CI was >0.75 (shown in bold). P values <0.05 are also shown in bold.

The level of activity, behaviour, appetite and interaction scores ranged from 0 to 3. The global owner score ranged from 0 to 12.